Significant Ownership of Paragon Therapeutics, Inc.
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Paragon Therapeutics, Inc. focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Keri Lantz - Keri Lantz, Chief Financial Officer
- Manager location
- Philadelphia, PA
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Paragon Therapeutics, Inc. with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Paragon Therapeutics, Inc.
Significant Ownership of Paragon Therapeutics, Inc.
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| GLTO | Galecto, Inc. | Common Stock, par value $0.00001 per share | 7.5% | $3,494,922 | 120,473 | Paragon Therapeutics, Inc. | 10 Nov 2025 | ||
| GLTO | Damora Therapeutics, Inc. | Common Stock, par value $0.00001 per share | 3.4% | 2,045,473 | Paragon Therapeutics, Inc. | 09 Feb 2026 |
Schedules 13D/G Reported by Paragon Therapeutics, Inc.:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.